A phase 1 randomised double blind, placebo-controlled, single dose, dose escalation study of the safety and tolerability profile of KB002, a chimeric monoclonal antibody which binds to granulocyte macrophage-colony stimulating factor (GM-CSF), in patients with rheumatoid arthritis.
Phase of Trial: Phase I/II
Latest Information Update: 07 Aug 2017
At a glance
- Drugs KB 002 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Humanigen; KaloBios Pharmaceuticals
- 07 Aug 2017 According to a Humanigen media release, KaloBios Pharmaceuticals changed its name to Humanigen.
- 13 Nov 2006 New trial record.